Thursday, July 05, 2012 4:53:29 AM
Study 1310 will now continue until such time that either all of the treated patients have received an open label treatment for a subsequent HAE attack, or until 90 days have lapsed since their randomized attack. This will be followed by the analysis of the results. Positive results of the study will trigger a US$ 10 million m ilestone payment to Pharming from its US partner Santarus Inc.
Currently 53 of the 75 patients have experienced a repeat attack or achieved a 90 day attack free period.
Bruno Giannetti, COO of Pharming, said, “Completion of recruitment into this clinical study is an important milestone for Pharming. As previously stated, the final step to completion of the trial consists of an additional follow up period of up to 90 days, depending on when patients experience a subsequent attack.
However, it is a generally accepted assumption that approximately one to two attacks occur per month in otherwise untreated HAE patients, suggesting that those individuals in our study may typically experience a subsequent attack significantly sooner than 90 days post their randomized attack.”
Recent PHARM News
- Pharming Group to participate in September investor conferences • GlobeNewswire Inc. • 09/04/2024 05:00:00 AM
- Pharming Group reports second quarter and first half 2024 financial results and provides business update • GlobeNewswire Inc. • 08/01/2024 05:00:00 AM
- Pharming Group to report second quarter and first half 2024 financial results on August 1 • GlobeNewswire Inc. • 07/18/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union • GlobeNewswire Inc. • 05/30/2024 08:44:24 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 05/15/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group to report first quarter 2024 financial results on May 8 • GlobeNewswire Inc. • 04/24/2024 06:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/19/2024 04:43:36 PM
- Pharming Group announces the placement of €100 million convertible bonds due 2029 • GlobeNewswire Inc. • 04/18/2024 01:04:30 PM
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/18/2024 06:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming Group announces the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/04/2024 06:30:00 AM
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F • GlobeNewswire Inc. • 04/04/2024 05:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM